Abstract: Medicaments and therapeutic compositions comprise Red Yeast Rice extract and omega-3 polyunsaturated fatty acids and/or derivatives thereof, e.g., DHA, derivatives of DHA, EPA, derivatives of EPA or mixtures thereof. One source of the fatty acids or derivatives thereof is fish oil. The compositions are useful for lowering cholesterol and/or triglyceride levels in a subject.

Abstract: Uniform, functional polymer patches can be attached to a fraction of the surface area of living individual cells. These surface-modified cells can cross the blood-brain barrier while remaining viable after attachment of the functional patch. Functional payloads carried by the patch can include a drug. The patch can include one or more polyelectrolyte multilayers (PEMs).

Abstract: The disclosure features methods for treating craniosynostosis in a patient (e.g., a patient having hypophosphatasia (HPP) and exhibiting or likely to have increased intracranial pressure (ICP)) by administering a soluble alkaline phosphatase (sALP) to the patient, e.g., in combination with a cranial surgery, e.g., a cranial vault remodeling procedure.

Abstract: The present invention provides a method capable of easily mixing any liquid containing a linking substance such as a divalent metal cation and the like with a liquid containing a particular compound at a high concentration, and capable of producing a liquid medium composition comprising fine structures dispersed therein, and a production device therefor and a kit therefor. The first liquid containing a particular compound is passed through a through-hole having a given cross-sectional area formed in a nozzle part at a given flow rate and injected into the second liquid at a given flow rate. By this simple operation, a structure in which the particular compound is bonded via the linking substance is formed, and the structure is preferably dispersed in a mixture of the both liquids.

Abstract: Provided is a novel agent for improving sleep quality. An agent for improving sleep quality containing, as an active ingredient, bacterial cells of Lactobacillus casei and/or a treated product thereof.

Abstract: A pharmaceutical composition comprising: a) an effective amount of one or more lytic bacteriophages specific against Fusobacterium nucleatum selected from Fnp?02-14, Fnp?11 and Fnn?107 or mixtures of them; and b) one or more pharmaceutically acceptable carrier and/or excipients. Method for preventing and/or treating diseases associated with Fusobacterium nucleatum and the use of the pharmaceutical composition for treating a disease associated with Fusobacterium nucleatum of the oral cavity such as V periodontal disease, among others.

Abstract: Spheroid microtissues that can mimic native tissue-like structure and function, spheroid production methods that are high-throughput, suitable for efficient production, maintainable over long-term culture, and/or offer repeatable control over size distribution. Spheroids that have blood vessels, including spheroids with functional, blood-perfused vascular networks upon injection in vivo. Dissolvable hydrogel microwell arrays for high throughput parallel formation of spheroids in a single pipetting step and easy retrieval for downstream applications. A method to produce prevascularized microtissues in sufficient numbers to form a macrotissue in vivo for therapeutic purposes. This method is based on sacrificial release of dissolvable microwell templates, a novel and scalable strategy which enables gentle harvesting of microtissues with control over size and composition.

Abstract: An apparatus and kit for performing water testing and a method for using the same.

Abstract: Provided are CD4+ T-cell-based compositions and methods for treating hypertension.

Abstract: Provided herein are compositions, methods, systems and/or kits for detection of bacteria expressing enzymes that confer resistance to antimicrobial agents. Certain embodiments of the compositions, methods, systems and/or kits of the present disclosure are related to detection of carbapenemase-producing gram negative bacteria. Certain embodiments of the compositions, methods, systems and/or kits of the present disclosure are related to detection of Ambler Class A, B and/or D carbapenemase-producing enteric and non-fermenting gram negative rod bacteria.

Abstract: The present subject matter is directed to a composition for staining cytological material comprising a cationic dye component, a hygroscopic polyol and optionally a water-soluble solvent, water or water-miscible solvent, methods of use of the compositions. Advantageously, the present compositions do not require the use of a cover slide as is required in known staining fixatives. The compositions are able to retain cell morphology for a period of time such that a cover slide is not required. Further, the compositions do not contain hazardous levels of organic components. Preferably, the compositions consist essentially of Azure C, glycerol and optionally water. In another aspect, the present subject matter is directed to a method of characterizing a cell sample comprising contacting the cell sample with a composition comprising a dye component and a hygroscopic polyol and subjecting the sample to analysis to determine the presence or absence of abnormal cells.

Abstract: A modular engineered tissue construct includes a plurality of fused self-assembled, scaffold-free, high-density cell aggregates. At least one cell aggregate includes a plurality of cells and a plurality of biocompatible and biodegradable nanoparticles and/or microparticles that are incorporated within the cell aggregates. The nanoparticles and/or microparticles acting as a bulking agent within the cell aggregate to increase the cell aggregate size and/or thickness and improve the mechanical properties of the cell aggregate as well as to deliver bioactive agents.

Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an iduronate-2-sulfatase (I2S) protein, salt, and a polysorbate surfactant for the treatment of Hunters Syndrome.

Abstract: Large volume cellular material may be preserved by combining the cellular material with a cryoprotectant formulation/medium/solution containing at least one sugar and then subjecting the cellular material to a vitrification preservation protocol.

Abstract: The present invention is related to a method for diagnosing Niemann-Pick disease in a subject comprising a step a), wherein the step a) comprises detecting a biomarker in a sample from the subject.

Abstract: A method for culturing cells by which the diameter of cell aggregates can be controlled, and by which a large amount of cells can be obtained, a cell aggregate obtained by the method, a cell aggregation control agent, and a medium containing the cell aggregation control agent, are provided. A method for culturing cells by suspension culture, which method includes an aggregation control step of adding a substance that inhibits a cell adhesion molecule(s) of the cells to a medium to control cell aggregation of the cells, and the like are provided.

Abstract: Compositions suitable for application to plants and seeds comprising dried Chlorella cells are disclosed. Methods of preparing and applying compositions of dried Chlorella cells to plants and seeds to enhance at least one characteristic of a plant are disclosed.

Abstract: A process and system directed to a more effective, individual based treatment regimen which is built on clinical identified target biomarkers associated with gender differential responses to mesalamine, and includes one or more panels of target biomarkers that distinguishes mesalamine response differences between genders and determines the efficacy of mesalamine for patients being treated for various UC conditions and effectively identifies and validates novel drug targets for new UC therapeutics, new diagnostics and diagnostics standards for UC therapeutic strategies.

Abstract: Disclosed are methods of determining activity of CDK4 and CDK6 variants upon exposure to CDK inhibitors, methods for determining activity of a Rb variant, methods for determining the activity of a p16 variant in a cell, and methods for determining the sensitivity of a CDK4 variant or a CDK6 variant to p16 in a cell. Stable cell lines for determining activity of CDK4 variants, CDK6 variants, Rb variants, and p16 variants are also disclosed.

Abstract: A highly-sensitive-allergen-measurement method is provided. A method for detecting an allergen in a sample comprises treating the sample with a protease, and detecting the presence or absence of an allergen-derived polypeptide in the enzymatically treated sample by a chromatographic separation analysis, wherein the allergen is one or more members selected from the group consisting of buckwheat, crustacean, milk, egg and peanut.